WHO New Guidelines for Alternative Mass Drug Administration Regimens for Lymphatic Filariasis
WHO published new guidelines for alternative Mass Drug Administration (MDA) regimens for Lymphatic Filariasis (LF) in the Weekly Epidemiological Record. The new guidelines recommend:
- Triple drug therapy (IDA) for use in countries using diethylcarbamazine + albendazole (DA) in special settings
- Annual ivermectin + albendazole (IA) rather than biannual IA in countries endemic for LF and onchocerciasis, except in areas already distributing biannual ivermectin for onchocerciasis
- Biannual albendazole rather than annual ablendazole in implementation units where LF is co-endemic with loiasis and ivermectin has not already been distributed
The DOLF (Death to Oncho and LF) studies provided important evidence to support these guidelines. The guidelines are tangible evidence that DOLF is making a policy impact that may translate to programmatic impact and the ultimate elimination of Lymphatic Filariasis globally.
SPRI is honored to have worked with the sponsors (Washington University, Case Western and the Bill and Melinda Gates Foundation) along with the incredible individuals on the ground in each country who spent hours day and night collecting blood, preparing blood smears, staring into microscopes, and entering or analyzing data.
It is amazing to imagine we are getting closer to a world free of Lymphatic Filariasis!